HAYWARD, California., August 11, 2022 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically controlled settings, announced today that an abstract entitled “Experience in Complex Ambulant Plastic Surgery Procedures Using Sufentanil Sublingual Tablets” was accepted for a panel presentation Plastic Surgery: The 2022 Meetingoccur 27-30 October 2022 in Boston, MA.
The abstracts will be presented and driven off at the conference Thursday 27 October 2022 at 1:30 p.m until Sunday 30 October 2022 at 4:30 p.m. ET. The timing of the panel presentation is yet to be announced, but will be posted on the Investors/Events section of the AcelRx website once this information becomes available. The presentation will only be conducted as a face-to-face event, without a virtual or repeat option being made available.
About Plastic Surgery: The 2022 Meeting
Plastic Surgery: The Meeting brings together plastic surgeons from countries around the world. This annual event is the premier educational and networking event of the year for national and international plastic surgeons and is considered the annual meeting of the American Society of Plastic Surgeons (ASPS). ASPS is the world’s largest professional plastic surgery organization, representing 94% of all board-certified plastic surgeons in the US, including more than 11,000 plastic surgeons worldwide. ASPS is recognized as a global institution and leading authority in the field of cosmetic and reconstructive plastic surgery. The meeting also brings together members of the Plastic Surgery Foundation (PSF), the American Society of Maxillofacial Surgeons (ASMS) and the World Society for Simulation Surgery.
About DSUVIA (Sufentanil Sublingual Tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings such as hospitals, surgical centers and emergency departments for the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DSUVIA is designed to provide rapid analgesia via a non-invasive route, eliminating dosing errors associated with intravenous (IV) administration. DSUVIA is a single strength solid dosage form that is administered sublingually via a single dose applicator (SDA) by a healthcare professional. Sufentanil is an opioid analgesic previously marketed only for IV and epidural anesthesia and analgesia. The pharmacokinetic profile of sufentanil when administered sublingually avoids the high peak plasma levels and short duration of action seen with intravenous administration. DZUVEO has been approved by the European Medicines Agency and AcelRx’s European commercialization partner, Aguettant, will commercialize the drug Europe.
This press release is intended for investors only. For more information, including important safety information and black box warnings for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically controlled settings. AcelRx’s proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has a US-approved product, DSUVIA® (Sufentanil Sublingual Tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the treatment of acute pain severe enough to require an opioid analgesic for adult patients in accredited medically supervised healthcare settings, and multiple product candidates. Product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the US being developed as an innovatively designed patient-controlled analgesic (PCA) system for the relief of moderate to severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes containing ephedrine and phenylephrine licensed for the United States from Aguettant; Niyad™, a regional anticoagulant for extracorporeal circulation; and LTX-608 for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEO is an approved product in Europe.
This press release is intended for investors only. For more information on AcelRx, visit www.acelrx.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-abstract-acceptance-for-podium-presentation-at-plastic-surgery-the-meeting -2022-301603983.html
SOURCE AcelRx Pharmaceuticals, Inc.